BD Announces FDA 510(k) Clearance Of BD ProbeTec™ Qx Amplified Assays For The Detection Of Chlamydia Trachomatis And Neisseria Gonorrhoeae

BD Announces FDA 510(k) Clearance Of BD ProbeTec™ Qx Amplified Assays For The Detection Of Chlamydia Trachomatis And Neisseria Gonorrhoeae

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the BD ProbeTec™ Chlamydia trachomatis (CT) Qx Amplified DNA Assay and the BD ProbeTec™ Neisseria gonorrhoeae (GC) Qx Amplified DNA Assay on the next-generation BD Viper™ System with XTR™ Technology."